DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

Dextrose provides a source of calories and fluid, correcting hypoglycemia. Sodium chloride and potassium chloride replenish electrolytes and maintain osmotic balance.

What the body does with it

Metabolism	Dextrose undergoes glycolysis and oxidative metabolism via the Krebs cycle; potassium is primarily excreted renally; sodium and chloride are handled by renal regulation.
Excretion	Dextrose is metabolized to carbon dioxide and water, with negligible renal excretion. Sodium and chloride are primarily excreted renally, with >90% eliminated unchanged; potassium is >90% renally excreted, with minor fecal (approximately 5%) and negligible biliary elimination.
Half-life	The components do not have a classical half-life. Dextrose has a distribution half-life of a few minutes and an elimination half-life of approximately 1-2 hours due to cellular uptake and metabolism. Sodium and chloride have a volume-dependent half-life; potassium's elimination half-life is approximately 12-24 hours, prolonged in renal impairment.
Protein binding	Dextrose, sodium, chloride, and potassium are not significantly protein-bound (<1%); potassium has minimal binding (~3% to albumin).
Volume of Distribution	Dextrose 0.2-0.3 L/kg (mainly extracellular); sodium and chloride distribution approximates extracellular fluid volume (~0.2 L/kg); potassium distribution is 0.4-0.5 L/kg (mainly intracellular).
Bioavailability	Intravenous: 100% for all components. Not administered orally for dextrose 5% with electrolytes due to GI tolerability issues; oral potassium has bioavailability ~90%.
Onset of Action	Intravenous: immediate for volume expansion; dextrose metabolism begins within minutes; potassium distribution occurs over minutes to hours.
Duration of Action	Volume effects last 1-2 hours; dextrose's caloric effect persists for 1-2 hours; potassium's effect on serum concentration lasts 4-6 hours, but tissue repletion requires longer infusion (e.g., 10-20 hours for deficit correction).

Classification & Brands

Dosing & administration

Intravenous infusion: 1000 mL administered at a rate of 125 mL/hour over 8 hours; typical dosing range 1-3 L per 24 hours titrated based on electrolyte levels, fluid status, and clinical response.

Dosage form	INJECTABLE
Renal impairment	eGFR 30-50 mL/min: reduce potassium content or use alternative; eGFR 15-29 mL/min: avoid if possible, use with caution and monitor potassium closely; eGFR <15 mL/min: contraindicated unless replacement therapy.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: monitor potassium and glucose levels; Child-Pugh Class C: use with caution, monitor for fluid overload and electrolyte imbalance.
Pediatric use	Dose based on weight and electrolyte needs; typical infusion rate 2-6 mL/kg/hour for maintenance; adjust potassium to 0.5-1 mEq/kg/day for replacement; maximum infusion rate not to exceed 1 mEq/kg/hour for potassium.
Geriatric use	Use lower end of dosing range due to decreased renal function; monitor for fluid overload, hyperkalemia, and glucose intolerance; typical rate 50-100 mL/hour adjusted based on renal function and volume status.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Dextrose, sodium, and potassium are normal constituents of breast milk. No adverse effects expected at maternal therapeutic doses. M/P ratio: Not applicable, as endogenous compounds; no specific data available.
Teratogenic Risk	Dextrose, sodium chloride, and potassium chloride are essential nutrients and electrolytes; no teratogenic effects are expected at therapeutic doses. Trimester 1: No known fetal risk. Trimester 2 & 3: Use as clinically indicated; excess potassium or sodium may cause maternal electrolyte disturbances affecting fetal fluid balance, but no direct teratogenicity.

Warnings & precautions

■ FDA Black Box Warning

None for this specific combination; however, potassium chloride carries risk of hyperkalemia and cardiac arrest if administered too rapidly or in renal impairment.

Side Effect Profile

Common Effects	fluid replacement
Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal impairment (anuria or oliguria)","Hypernatremia","Fluid overload (pulmonary edema)","Severe dehydration with oliguria","Potassium sensitivity"]

Clinical Precautions

Precautions

["Monitor serum electrolytes, renal function, and fluid balance","Risk of hyperkalemia, especially in renal impairment","Risk of fluid overload, pulmonary edema","Use with caution in patients with heart failure, renal impairment, or hyperkalemia","Do not use as a potassium replacement in severe hyperkalemia"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

Dextrose provides a source of calories and fluid, correcting hypoglycemia. Sodium chloride and potassium chloride replenish electrolytes and maintain osmotic balance.

What the body does with it

Metabolism	Dextrose undergoes glycolysis and oxidative metabolism via the Krebs cycle; potassium is primarily excreted renally; sodium and chloride are handled by renal regulation.
Excretion	Dextrose is metabolized to carbon dioxide and water, with negligible renal excretion. Sodium and chloride are primarily excreted renally, with >90% eliminated unchanged; potassium is >90% renally excreted, with minor fecal (approximately 5%) and negligible biliary elimination.
Half-life	The components do not have a classical half-life. Dextrose has a distribution half-life of a few minutes and an elimination half-life of approximately 1-2 hours due to cellular uptake and metabolism. Sodium and chloride have a volume-dependent half-life; potassium's elimination half-life is approximately 12-24 hours, prolonged in renal impairment.
Protein binding	Dextrose, sodium, chloride, and potassium are not significantly protein-bound (<1%); potassium has minimal binding (~3% to albumin).
Volume of Distribution	Dextrose 0.2-0.3 L/kg (mainly extracellular); sodium and chloride distribution approximates extracellular fluid volume (~0.2 L/kg); potassium distribution is 0.4-0.5 L/kg (mainly intracellular).
Bioavailability	Intravenous: 100% for all components. Not administered orally for dextrose 5% with electrolytes due to GI tolerability issues; oral potassium has bioavailability ~90%.
Onset of Action	Intravenous: immediate for volume expansion; dextrose metabolism begins within minutes; potassium distribution occurs over minutes to hours.
Duration of Action	Volume effects last 1-2 hours; dextrose's caloric effect persists for 1-2 hours; potassium's effect on serum concentration lasts 4-6 hours, but tissue repletion requires longer infusion (e.g., 10-20 hours for deficit correction).

Classification & Brands

Dosing & administration

Intravenous infusion: 1000 mL administered at a rate of 125 mL/hour over 8 hours; typical dosing range 1-3 L per 24 hours titrated based on electrolyte levels, fluid status, and clinical response.

Dosage form	INJECTABLE
Renal impairment	eGFR 30-50 mL/min: reduce potassium content or use alternative; eGFR 15-29 mL/min: avoid if possible, use with caution and monitor potassium closely; eGFR <15 mL/min: contraindicated unless replacement therapy.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: monitor potassium and glucose levels; Child-Pugh Class C: use with caution, monitor for fluid overload and electrolyte imbalance.
Pediatric use	Dose based on weight and electrolyte needs; typical infusion rate 2-6 mL/kg/hour for maintenance; adjust potassium to 0.5-1 mEq/kg/day for replacement; maximum infusion rate not to exceed 1 mEq/kg/hour for potassium.
Geriatric use	Use lower end of dosing range due to decreased renal function; monitor for fluid overload, hyperkalemia, and glucose intolerance; typical rate 50-100 mL/hour adjusted based on renal function and volume status.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Dextrose, sodium, and potassium are normal constituents of breast milk. No adverse effects expected at maternal therapeutic doses. M/P ratio: Not applicable, as endogenous compounds; no specific data available.
Teratogenic Risk	Dextrose, sodium chloride, and potassium chloride are essential nutrients and electrolytes; no teratogenic effects are expected at therapeutic doses. Trimester 1: No known fetal risk. Trimester 2 & 3: Use as clinically indicated; excess potassium or sodium may cause maternal electrolyte disturbances affecting fetal fluid balance, but no direct teratogenicity.

Warnings & precautions

■ FDA Black Box Warning

None for this specific combination; however, potassium chloride carries risk of hyperkalemia and cardiac arrest if administered too rapidly or in renal impairment.

Side Effect Profile

Common Effects	fluid replacement
Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal impairment (anuria or oliguria)","Hypernatremia","Fluid overload (pulmonary edema)","Severe dehydration with oliguria","Potassium sensitivity"]